TCGA-MT-A67F-01A-11R-A30B-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.670
- INTERFERON_GAMMA_RESPONSE+0.650
- TNFA_SIGNALING_VIA_NFKB+0.650
- ALLOGRAFT_REJECTION+0.610
- IL6_JAK_STAT3_SIGNALING+0.590
- INFLAMMATORY_RESPONSE+0.550
- COMPLEMENT+0.460
- KRAS_SIGNALING_UP+0.420
- APOPTOSIS+0.390
- IL2_STAT5_SIGNALING+0.380
Top 10 suppressed
- MYC_TARGETS_V2-0.430
- E2F_TARGETS-0.300
- G2M_CHECKPOINT-0.280
- MYOGENESIS-0.280
- NOTCH_SIGNALING-0.230
- SPERMATOGENESIS-0.220
- ADIPOGENESIS-0.180
- HEDGEHOG_SIGNALING-0.160
- MITOTIC_SPINDLE-0.150
- FATTY_ACID_METABOLISM-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR13780252 | — | cohortMD2 | 0.893 |
| 2 | TCGA-75-5122-01A-01R-1755-07 | — | cohortA1 | 0.881 |
| 3 | SRR9879272 | — | cohortSQ1 | 0.877 |
| 4 | BS_5AF6ZNJF | Meningioma | — | 0.855 |
| 5 | C3N-03765 | — | cohortA1 | 0.854 |
| 6 | TCGA-CN-5369-01A-01R-1436-07 | — | — | 0.854 |
| 7 | SRR8518406 | — | D | 0.853 |
| 8 | SRR810571 | GTEX | — | 0.849 |
| 9 | BS_B7QS4DHK | Schwannoma | — | 0.848 |
| 10 | C3N-02242 | — | cohortA1 | 0.846 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.670 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.650 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.650 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.610 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.590 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.550 | Idelalisib | — uncovered |
| COMPLEMENT | 0.460 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.420 | Inavolisib | — uncovered |
| APOPTOSIS | 0.390 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.380 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.360 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.340 | Remibrutinib | — uncovered |
| COAGULATION | 0.310 | Binimetinib | — uncovered |
| HYPOXIA | 0.290 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.160 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.150 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.140 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.130 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.120 | Temsirolimus | — uncovered |
| HEME_METABOLISM | 0.120 | Temsirolimus | — uncovered |